Xconomy.com, a website that covers technology and innovation in major cities around the country, has opened a bureau in Raleigh to cover the North Carolina market.
Founder Bob Buderi writes, “In each region, Xconomy reporters deliver daily stories about the high-tech and life science startups, bigger companies, investors, and innovators driving growth in the economy. But we don’t just jump on any story: we try to find the local story with global impact. That is, the story all too often missing from wider press coverage, but that deserves more of the limelight. And that, we believe, is our secret sauce when opening a new bureau: we bring stories of that region to a fast-growing, highly sophisticated business audience not just around the U.S., but around the world (25 percent of our traffic is from outside the United States).
“And so it will be with North Carolina. Xconomy editors from around the network have teamed up to begin our coverage—and we’ll be rolling out their stories over the next few weeks, along with guest posts from our North Carolina Xconomists, or informal editorial advisors. It all starts today with a story from our on-the-ground writer Frank Vinluan, who’s delivered his personal take on the North Carolina innovation scene as well as a profile of BioCryst Pharmaceuticals, a small biotech that is developing what it hopes will become the first treatment targeting the Ebola virus. Along with that, Xconomy contributing editor Wade Roush offers an in-depth piece on ThinkHouse, a Raleigh-based live-in startup accelerator. And Xconomist Christy Shaffer of Hatteras Ventures has posted her from the heart, personal recollection on Research Triangle Park.
“In that short list lies a hint of the wide variety of coverage we plan to deliver going forward. Many think of innovation in North Carolina as Research Triangle Park and its world-class concentration of life science companies like GlaxoSmithKline, Syngenta, Biogen Idec, or Bayer CropScience — all of which have large operations in RTP — along with smaller companies and biotech startups.”
Read more here.
